Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | EP300 | Q09472 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17604699 | 0.88 | CYP2C19 (0.49) | CYP2C19EP300KMT2APOLBMEN1 | |
| SCHEMBL17606326 | 0.87 | CYP2C19 (0.66) | CYP2C19EP300KMT2APOLBMEN1 | |
| SCHEMBL17605478 | 0.85 | POLB (0.63) | KMT2APOLBMEN1MAPTLMNA | |
| SCHEMBL17605480 | 0.85 | POLB (0.63) | KMT2APOLBMEN1MAPTLMNA | |
| SCHEMBL17605083 | 0.84 | EP300 (0.57) | CYP2C19EP300KMT2AMEN1MAPT | |
| SCHEMBL17605268 | 0.84 | KMT2A (0.41) | CYP2C19KMT2APOLBMEN1MAPT | |
| SCHEMBL17605929 | 0.84 | KMT2A (0.53) | CYP2C19EP300KMT2APOLBMEN1 | |
| SCHEMBL17606568 | 0.82 | CYP2C19 (0.44) | CYP2C19EP300KMT2APOLBMEN1 | |
| SCHEMBL17606404 | 0.82 | CYP2C19 (0.44) | CYP2C19KMT2APOLBMEN1MAPT | |
| SCHEMBL17604724 | 0.79 | KMT2A (0.63) | CYP2C19KMT2APOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2016044770-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235716-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | CYP2C19 2587/4885EP300 5/4885KMT2A 127/4885 |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, KAT2A | CYP2C19 2256/4885EP300 6/4885KMT2A 97/4885 |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | CYP2C19 2587/4885EP300 5/4885KMT2A 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.